NFWHSF: Nanofat on Wound Healing and Scar Formation

Sponsor
Universitair Ziekenhuis Brussel (Other)
Overall Status
Unknown status
CT.gov ID
NCT03850119
Collaborator
(none)
15
2
36

Study Details

Study Description

Brief Summary

This study will evaluate the effectiveness and safety of intradermal injection of Nanofat on wound healing and scar formation.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Nanofat injection
N/A

Detailed Description

In this monocentric, randomized, controlled, double-blinded prospective interventional study, twenty patients will be included. Each patient will be his/her own control.

Patients undergoing DIEPflap breast reconstruction will be included in this study. During the surgery, the abdominal incision will be divided in two equal sides with the umbilicus as midline reference. The sides will be randomized in a treatment side and control side. The treatment side will receive intradermal nanofat injections after the subcutaneous and right before the intradermal sutures.

The patient and investigators will be blinded for the treatment protocol. The effects on wound healing, adverse events, scar formation and pigmentation will be evaluated up to one year after the surgery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
15 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
monocentric randomized controlled double-blinded prospective interventional studymonocentric randomized controlled double-blinded prospective interventional study
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Patient, investigator, outcome assessor will be blinded for which side of the scar was treated and which was a control. Only the surgeon, who will not be involved in the assessment, will not be blinded.
Primary Purpose:
Treatment
Official Title:
Nanofat on Wound Healing and Scar Formation: a Randomized, Split-scar, Double Blind Trial
Anticipated Study Start Date :
Mar 1, 2019
Anticipated Primary Completion Date :
Sep 1, 2021
Anticipated Study Completion Date :
Mar 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intradermal Nanofat

This side of the scar received intradermal injection of nanofat during the closure of the donor site.

Procedure: Nanofat injection
Lipoaspirate, harvested during the surgery, is centrifuged for 1 minute at 2000 rpm to discard infiltration fluid. The residual fat is passed back and forth between two 10cc syringes interlocked with Tulip connecting pieces (2.4, 1.4 and 1.2 diameter, each 10 passes for a total of 30 passes). This is injected intradermally before the intradermal sutures are placed. The donor site is always entirely sutured (both sides) by the same person.

No Intervention: Control

This side of the scar received no injection.

Outcome Measures

Primary Outcome Measures

  1. Clinical outcome of the abdominal scar by the use of Patient and Observer Scar Assessment Scale [one year]

    The abdominal scar will be evaluated clinically by the patient and observer scar assessment scale, starting from one month after the surgery

  2. Clinical assessment of the time to healing of the abdominal wound [one month]

    The time for the abdominal wound to heal will be registered. Wound healing is considered a closed and non-dehiscent wound witout signs of inflammation or infection.

  3. Evaluation of histological parameters on tissue biopsy from both sides of the abdominal scar. [six months]

    Evaluation of the histological differences of the treatment arm vs. control, by evaluating scar properties on tissue biopsy. Scar thickness, collagen arrangement and angiogenesis will be evaluated.

  4. Pigmentation Index of the two sides of the scar, measured with a Mexameter [one year]

    Evaluation of the Pigmentation Index difference in the treatment arm vs. control arm will be measured by the use of a mexameter, starting from one month after the procedure (after wound healing is complete).

  5. Patient satisfaction of abdominal scar appearance measured by a Visual Analog Scale [one year]

    Evaluation of patient satisfaction over the entire course of the study by filling in a Visual Analog Scale, with 1 being very unsatisfied and 10 being very satisfied.

  6. Rate of adverse events [One year]

    Registration of the rate of adverse events appearing at the abdominal wound/abdominal scar

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • scheduled for DIEP-flap breast reconstruction surgery at our department
Exclusion Criteria:
  • smokers

  • use of cortisone or other immunsuppressants

  • diabetes mellitus type 1 or 2

  • age

  • connective tissue disease

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Universitair Ziekenhuis Brussel

Investigators

  • Principal Investigator: Moustapha Hamdi, MD,PhD, Universitair Ziekenhuis Brussel

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Moustapha Hamdi, Head of department Plastic and Reconstructive surgery, Universitair Ziekenhuis Brussel
ClinicalTrials.gov Identifier:
NCT03850119
Other Study ID Numbers:
  • 2019-044
First Posted:
Feb 21, 2019
Last Update Posted:
Feb 21, 2019
Last Verified:
Feb 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Moustapha Hamdi, Head of department Plastic and Reconstructive surgery, Universitair Ziekenhuis Brussel
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 21, 2019